帕罗西汀联合米氮平治疗难治性抑郁症对照研究

目的：探讨帕罗西汀联合米氮平治疗难治性抑郁症的疗效和安全性。方法将56例难治性抑郁症患者分为两组，均口服帕罗西汀治疗，研究组在此基础上联合米氮平治疗，观察8周。于治疗前后采用汉密顿抑郁量表、汉密顿焦虑量表、副反应量表评定疗效和不良反应。结果治疗8周末研究组显效率为67．9％、总有效率为92．9％，对照组分别为25．0％、78．6％，研究组显效率显著高于对照组（ P＜0．01）。研究组不良反应发生率为35．7％，对照组为32．1％，两组比较差异无显著性（P＞0．05）。结论帕罗西汀联合米氮平治疗难治性抑郁症起效快，疗效显著，安全性高，优于单用帕罗西汀治疗。

A control study of paroxetine combined with mirtazapine in the treatment of treatment-resistant depression

Objective To explore the efficacy and safety of paroxetine combined with mirtazapine in the treatment of treatment-resistant depression （TRD） .Methods Fifty-six TRD pa-tients were divided into two groups taking orally paroxetine ,on this basis research group was plus mirtazapine for 8 weeks .Before and after treatment efficacies were assessed with the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA ） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 8th week obvious and total effective rate were respec-tively 67 .9% and 92 .9% in research and 25 .0% and 78 .6% in control group ,obvious effective rate was significantly higher in research than in control group （P〈0 .01） .The incidence of adverse reaction was respectively 35 .7% in research and 32 .1% in control group and had no significant group difference （ P〉0 .05） .Conclusion Paroxetine combined with mirtazapine in the treatment of TRD takes effect more rapidly and has an evident effect and higher safety compared with single paroxetine .